BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of December 30, 2025, BMY stock price declined to $54.09 with 3,706,434 million shares trading.

BMY has a beta of 0.41, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.06 to the broad based SPY ETF.

BMY has a market cap of $110.06 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $12 billion in Revenue and $1.63 earnings per share. This beat revenue expectation by $410 million and exceeded earnings estimates by $.12.

In the last 3 years, BMY traded as high as $75.18 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.

BMY has underperformed the market in the last year with a price return of -1.9% while the SPY ETF gained +16.8%. However, in the short term, BMY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.9% vs +3.9% return in SPY. But in the last 2 weeks, BMY shares have been beat by the market, returning -0.4% compared to an SPY return of +1.3%.

BMY support price is $53.20 and resistance is $55.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.